paoper

Geissospermum vellosi (Pao Pereira)

This page report syntethically principal information about GEISSOSPERMUM VELLOSI (PAO PEREIRA) and HIV. The complete research text is available only in Italian language and is published in the volume: Bianchi, Adamoli, " Piante Medicinali e AIDS", Ed. Tecniche Nuove, 1997. For a better result we suggest to print this document in landscape mode.

IN VITRO DATA

Geissospermum vellosi inhibits reverse transcriptasi, through a particular action, that is, fixing itself over genoma and stopping inverse transcriptasi action (Beljans K.I. 1993b; Beljans K.I. 1995a). Gv modulates TNF- a and IL-6 production (Damais 1993). Gv effectiveness and safe have been contested by Agence Nationale de Recherche Sur la Sida (ANRS), In France, that on June, 1994, made some in vitro tests with not effective and toxic results (Perez 1994). A following in vitro test made by Walter Reed Hospital of Rockville, USA has differently showed that Gv inhibits, in vitro, viral stubs resistant to AZT with safe dosages (Mayers 1994, Avicenne 1995).

IN VIVO DATA

Duration (weeks) Type of Study Principal Markers and
Study stage (F)
Starting CD4
(mm³)
and/or Stage
Starting Viral Load(CV) (copies/ml) Results Treated Controls Total treated cases

Reference Dosage

Donadio 1990/91 2000 mg/die (os) 43 SC Safety (F=I) Safe 20

Herold 1993 500-625 mg/die (os) A CC CD4 Var. Improvement 63

Donadio 1994 1000 mg/die (os) 56 SC CD4, CD4/CD8, p 24.
(F=I/II)
200-400 á CD4 e CD4/CD8,
Ag p24 M o SN
10

93

Clinical Data – Legenda
DNR = Data Not Available X = Media
M = Improves A = Years Me = Median
S = Synthesis N = Natural SN = Permanently
CC = Clinical Casuistics Negative
Q = Questionnaire S = Stabiliser
SCC = Controlled Cl. Study SA = Open Study
SO = Observational Study SC = Clinical Study

Considerations:

Some researches document the In Vtro action of PP extracts against HIV.
The relationship between the efficacy dosage and toxic dosage has not been completely clarified, even if the most part of the researches delineate the existence of a safety margin between toxic dosage and active dosage In Vitro. In addition, the ancient and widespread popular usage of PP in already titled in alkaloids formulations, suggests that at certain concentrations the PP extract is safe.
About the In Vivo efficacy of PP only a small clinical study is available, this doesn’t allow any complete evaluation. Anyway, this study and the presented casuistic indicate a probable action of PP against HIV and for this reason further study is desirable

Riferimenti bibliografici

Avicenne J (1994)
Le Pao Pereira: prometteur "malgré" Beljanski.
Positifs, p 60-64

Avicenne J (1995)
Pao pereira testé aux USA. Modes d’action. Limites des études in vitro.
Sida Tout Va Bien, n° 21, juillet 1995

Beljanski M. (1993a)
Nouvelle Strategie Biomédical
Centre de recherche biologique (CERBIOL) Saint Prim, France
(Pubblicazione autoprodotta)

Beljanski M. (1993b)
Une stratégie multifocale anti-HIV.
in Colloque Biomedical a cura del Centre de Recerche Biologique. Saint Prim France
(Pubblicazione autoprodotta)

Beljanski M, Crochet S, Beljanski MS (1993c)
PB100: A Potent and Selective Inhibitor of Human BCNU Resistant Glioblastoma Cell Multiplication
Anticancer Res, vol 13(6A): 2301-2308

Beljanski M. Crochet S. (1994a)
Selective inhibitor (PB100) of human glioblastoma cell multiplication
J Neuro-Oncol, vol 21: 62

Beljanski M. Crochet S. (1994b)
The selective Anticancer Agent PB-100 Inhibits Interleukin-6 Induced Enhancement of Glioblastoma Cell Proliferation in Vitro.
Int J Oncol, vol 5: 873-879

Beljanski M (1995a)
Pourquoi le PB-100 se comporte-t-il differemment que les antiretroviraux classiques.
In Colloque Biomedical a cura del Centre de recherche biologique (CERBIOL) Saint Prim, France
(Pubblicazione autoprodotta)

Beljanski M, Crochet S (1995b)
The Anticancer PB-100 Concentrates in the Nucleus and Nucleoli of Human Glioblastoma Cells but Does not Enter Normal Astrocytes.
Int J Oncol, vol 7: 81-85

Bertho A, von Schucumann G (1931)
Ber, vol 64: 2278

Bertho A, Moog F (1934)
Ann, vol 509: 241

Chiaroni A, Riche C, Pais M, Goutarel R (1976)
Alcaloides indoliques CIV¹: structure cristalline de la geissospermine
Tetrahedron Letters, n°51: 4729-4730, Pergamon Press

Courbet R (1994)
J’accuse. Lettre ouverte a Monsieur Edouard Balladur, Premier ministre.
Vous et votre Santé, n° special 1994

Damais C (1993)
Effect du produit H sur la production de cytokines primaires (IL-1b et TNF-a ) et secondaires (IL-6) par des monocytes normaux ou provenants de patients seropositifs.
Service Gentilini - Pitié Salpetrière
in: ISA Dossier (non pubblicato, ma allegato alla richiesta di AMM francese)

Donadio D (1990/1991)
Essai de tolerance et de faisibilité. Hospital Lapeyronie - Montpellier France
In: Abraxas BioLabs: Antiviral PB100 actif contre le VIH, Dossier n 2

Donadio D, Pontello G, Nawrocki T, Causse JE (1994)
Tolerance and Feasibility of a 12-Month Theraphy Using the Antiretroviral Agent PB100 in Aids-Related Complex patients
J Oncol, vol 26(6): 145-150

Ferreira H (1949)
Brasil Médico, 63:11

Freud M, Fauvet HF (1893)
Ber, 26: 1084

Freud M, Fauvet HF (1894)
Ann, 282: 247

Henry TA (1949)
The Plant Alkaloids
4^ ed., The Blakistan Co, Philadelphia, Pa

Herold MR (1993)
Note de synthèse sur 63 dossiers cliniques de patients seropositifs traités par le PB100 en essai ouvert.
in: Antiviral PB100 actif contre le VIH. Dossier n 2, a cura di Abraxas BioLabs

Hesse O (1880)
Ann. 202: 141

Hughes NA, Rapaport H (1958)
Flavopereirine: an Alkaloid from Geissospermum vellosii.
J Am Chem Soc, vol 80: 1604-1608

Jachertz D (1989)
Destruction of HIV in Vitro Cells without Effect on Normal Cells.
in: Colloque Biomédical a cura del Centre de Recherche Biologique (CERBIOL) Saint Prim France (Pubblicazione autoprodotta).

Lu Wei e Andrieu JM (1992)
Activity of Compound H on in-vitro HIV Infection.
Laboratory of Tumor-Immunology. Hospital Laennec. Université de Paris.
in: Colloque Biomedical a cura del Centre de Recherche Biologique (CERBIOL) Saint Prim France (Pubblicazione autoprodotta).

Mayers DM (1994)
Ricerca effettuata presso l’HIV Drug and Gene Therapy Department. Walter Reed Army Institute of Research.
in Colloque Biomédical a cura del Centre de Recherche Biologique (CERBIOL) Saint Prim France.

Perez M (1994)
Sida: la potion Beljanski rejetée après exames
Figaro, 25/6/1994

Rapoport H; Onak TP, Hughes NA, Reinecke MG (1958)
Alkaloids of Geissospermum Vellosii.
J Am Chem Soc, vol 80: 1601-1603

Ribeiro JE Caden Souccar, Lapa AJ (1984)
Mecanismo da Acao Curarizante dos Alcaloides do Pau Pereira
VIII Simposio de Plantas Medicinais do Brasil, p. 36, 4-6 Setembro, Manaus

			Duration (weeks)	Type of Study	Principal Markers and Study stage (F)	Starting CD4 (mm³) and/or Stage	Starting Viral Load(CV) (copies/ml)	Results	Treated	Controls	Total treated cases
Reference		Dosage	Duration (weeks)	Type of Study	Principal Markers and Study stage (F)	Starting CD4 (mm³) and/or Stage	Starting Viral Load(CV) (copies/ml)	Results			Total treated cases
Donadio 1990/91	2000 mg/die (os)		43	SC	Safety (F=I)			Safe	20
Herold 1993	500-625 mg/die (os)		A	CC	CD4	Var.		Improvement	63
Donadio 1994	1000 mg/die (os)		56	SC	CD4, CD4/CD8, p 24. (F=I/II)	200-400		á CD4 e CD4/CD8, Ag p24 M o SN	10
											93